Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease.

Yuditskaya S, Tumblin A, Hoehn GT, Wang G, Drake SK, Xu X, Ying S, Chi AH, Remaley AT, Shen RF, Munson PJ, Suffredini AF, Kato GJ.

Blood. 2009 Jan 29;113(5):1122-8. doi: 10.1182/blood-2008-03-142604.

2.

Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease.

Tumblin A, Tailor A, Hoehn GT, Mack AK, Mendelsohn L, Freeman L, Xu X, Remaley AT, Munson PJ, Suffredini AF, Kato GJ.

Haematologica. 2010 Sep;95(9):1467-72. doi: 10.3324/haematol.2009.018044.

3.

Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension.

Zorca S, Freeman L, Hildesheim M, Allen D, Remaley AT, Taylor JG 6th, Kato GJ.

Br J Haematol. 2010 May;149(3):436-45. doi: 10.1111/j.1365-2141.2010.08109.x.

4.

Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia.

Odhiambo A, Perlman DH, Huang H, Costello CE, Farber HW, Steinberg MH, McComb ME, Klings ES.

Rapid Commun Mass Spectrom. 2007;21(14):2195-203.

PMID:
17569101
5.

Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression.

Klings ES, Anton Bland D, Rosenman D, Princeton S, Odhiambo A, Li G, Bernard SA, Steinberg MH, Farber HW.

Am J Hematol. 2008 Jul;83(7):547-53. doi: 10.1002/ajh.21187.

6.

Lipoprotein subfraction profile and HDL-associated enzymes in sickle cell disease patients.

Ozturk OH, Can Y, Yonden Z, Motor S, Oktay G, Kaya H, Aslan M.

Lipids. 2013 Dec;48(12):1217-26. doi: 10.1007/s11745-013-3849-4.

PMID:
24113910
7.

Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT.

Blood. 2006 Mar 15;107(6):2279-85.

8.

Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

Kato GJ, Gladwin MT.

JAMA. 2008 Dec 10;300(22):2638-46. doi: 10.1001/jama.2008.598. Review.

9.
10.

Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker.

Lepedda AJ, Nieddu G, Zinellu E, De Muro P, Piredda F, Guarino A, Spirito R, Carta F, Turrini F, Formato M.

Oxid Med Cell Longev. 2013;2013:385214. doi: 10.1155/2013/385214.

11.

Association of pro-inflammatory high-density lipoprotein cholesterol with clinical and laboratory variables in sickle cell disease.

Ataga KI, Hinderliter A, Brittain JE, Jones S, Xu H, Cai J, Kim S, Pritchard KA, Hillery CA.

Hematology. 2015 Jun;20(5):289-96. doi: 10.1179/1607845414Y.0000000171.

12.

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH, Voest EE.

Ann Oncol. 2010 Jul;21(7):1472-81. doi: 10.1093/annonc/mdp559.

13.

Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria.

Aliyu ZY, Gordeuk V, Sachdev V, Babadoko A, Mamman AI, Akpanpe P, Attah E, Suleiman Y, Aliyu N, Yusuf J, Mendelsohn L, Kato GJ, Gladwin MT.

Am J Hematol. 2008 Jun;83(6):485-90. doi: 10.1002/ajh.21162.

14.

Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension.

Landburg PP, Teerlink T, van Beers EJ, Muskiet FA, Kappers-Klunne MC, van Esser JW, Mac Gillavry MR, Biemond BJ, Brandjes DP, Duits AJ, Schnog JJ; CURAMA study group..

Haematologica. 2008 Sep;93(9):1410-2. doi: 10.3324/haematol.12928. No abstract available.

15.

Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.

Gordeuk VR, Castro OL, Machado RF.

Blood. 2016 Feb 18;127(7):820-8. doi: 10.1182/blood-2015-08-618561. Review.

PMID:
26758918
16.

Cerebrovascular disease associated with sickle cell pulmonary hypertension.

Kato GJ, Hsieh M, Machado R, Taylor J 6th, Little J, Butman JA, Lehky T, Tisdale J, Gladwin MT.

Am J Hematol. 2006 Jul;81(7):503-10.

17.

Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, Sohier C, Hinderliter A, Parise LV, Orringer EP.

Haematologica. 2008 Jan;93(1):20-6. doi: 10.3324/haematol.11763.

18.

Pulmonary artery occlusion pressure may overdiagnose pulmonary artery hypertension in sickle cell disease.

Sharma S, Efird J, Kadali R, Mehra S, Chohan H, Daggubati R, Liles D, Gouge C, Boettger P, Knupp C.

Clin Cardiol. 2013 Sep;36(9):524-30. doi: 10.1002/clc.22153.

19.

[Pulmonary arterial hypertension and sickle cell disease].

Savale L, Maitre B, Bachir D, Galactéros F, Simonneau G, Parent F.

Presse Med. 2013 Mar;42(3):338-46. doi: 10.1016/j.lpm.2012.04.021. French.

PMID:
22743045
20.

Dysregulation of ubiquitin-proteasome pathway and apolipoprotein A metabolism in sickle cell disease-related pulmonary arterial hypertension.

Anjum F, Lazar J, Soh J, Albitar M, Gowda S, Hussain MM, Wadgaonkar R.

Pulm Circ. 2013 Dec;3(4):851-5. doi: 10.1086/674763.

Items per page

Supplemental Content

Support Center